Description

BSE announces listing and admission for trading of new securities issued by 5 companies under ESOP/ESOS schemes, effective October 8, 2025.

Summary

BSE has announced the listing and admission for trading of further securities issued by five companies under their Employee Stock Option Plans (ESOP) and Employee Stock Option Schemes (ESOS). These new securities will be available for trading with effect from Wednesday, October 8, 2025. The circular provides details of share quantities, face values, and lock-in periods for each company.

Key Points

  • 5 companies have issued new securities under ESOP/ESOS schemes
  • Trading commencement date: October 8, 2025
  • Total new shares across all companies: 810,996 shares
  • Lock-in periods vary by company, with some securities having no lock-in and others locked until March 15, 2026
  • Companies include major players in pharma, banking, aviation, and coworking sectors

Company-wise Details

1. Bliss GVS Pharma Limited

  • Scrip Code: 506197
  • ISIN: INE416D01022
  • New Shares: 39,950
  • Face Value: ₹1
  • Lock-in Period: Until March 15, 2026

2. Federal Bank Ltd.

  • Scrip Code: 500469
  • ISIN: INE171A01029
  • New Shares: 44,995
  • Face Value: ₹2
  • Lock-in Period: None

3. IDFC FIRST Bank Limited

  • Scrip Code: 539437
  • ISIN: INE092T01019
  • New Shares: 576,888
  • Face Value: ₹10
  • Lock-in Period: None

4. InterGlobe Aviation Limited (IndiGo)

  • Scrip Code: 539448
  • ISIN: INE646L01027
  • New Shares: 25,063
  • Face Value: ₹10
  • Lock-in Period: None

5. Smartworks Coworking Spaces Limited

  • Scrip Code: 544447
  • ISIN: INE0NAZ01010
  • New Shares: 123,100
  • Face Value: ₹10
  • Lock-in Period: None

Regulatory Changes

No regulatory changes are introduced in this circular. This is a standard listing notification for securities issued under existing ESOP/ESOS frameworks.

Compliance Requirements

Trading members are informed of the new listings for their operational awareness. No specific compliance actions are required from trading members beyond standard trading procedures for newly listed securities.

Important Dates

  • Circular Date: October 7, 2025
  • Trading Commencement: October 8, 2025
  • Lock-in Expiry (Bliss GVS Pharma): March 15, 2026

Impact Assessment

Market Impact: Low - The issuance represents routine ESOP/ESOS conversions with minimal dilution effect on existing shareholding patterns. The total number of shares being listed is relatively small compared to the paid-up capital of these companies.

Liquidity Impact: Negligible - Most securities have no lock-in period, though their immediate trading volumes are expected to be limited given the employee-related nature of the issuance.

Investor Impact: Minimal - Existing investors may see marginal dilution in their holdings, but the impact is immaterial given the small quantum of shares relative to total outstanding equity.

Impact Justification

Routine listing of ESOP/ESOS securities with limited market impact; affects specific companies' share capital but does not involve regulatory changes or compliance requirements for trading members.